cas 4857-04-9|| where to buy 2-(chloromethyl)-1H-benzo[d]imidazole

製品名:2-(chloromethyl)-1H-benzo[d]imidazole

IUPAC Name:2-(chloromethyl)-1H-1,3-benzodiazole

包装単位	有効在庫	価格（USD）
CM100059-25g	in stock	ŗȃ
CM100059-100g	in stock	ƿƓŗ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

追記事項

Verification code*

refresh

: CAS番号:4857-04-9; 分子式:C8H7ClN2; 融点:-; SMILESコード:ClCC1=NC2=CC=CC=C2N1; 密度:1.356g/cm3

: カタログ番号:CM100059; 分子量:166.61; 沸点:371°C at 760 mmHg; MDL番号:MFCD00005602; 保管方法:Store at 2-8°C.

: Benzimidazoles; Benzimidazole is a benzo derivative of imidazole. It is a kind of bicyclic aromatic organic compounds, which is formed by fusing a six-membered benzene ring and five-membered imidazole at positions 4 and 5 of imidazole ring. It is an important pharmacophore of many biologically active heterocyclic compounds with various pharmacological activities. Benzimidazoles and their derivatives have developed into dynamic heterocyclic systems due to their potency in a variety of biologically active compounds such as anticancer, bactericidal and antiviral drugs. Benzimidazoles are a class of therapeutic motifs with broad relevance in medicinal chemistry.

: Benzo Heterocycles; Benzoheterocycles are heterocycles which are fused with a benzene ring. Coumarone, thianaphthene, benzopyridine, isoquinoline, and dibenzopyridine all belong to this class of compounds.

: Mavorixafor; X4 Pharmaceuticals’ lead product candidate, Mavorixafor (X4P-001) has reached a significant milestone with the submission of a New Drug Application (NDA) to the U.S. FDA for the treatment of WHIM Syndrome on September 5. This marks an important step forward in the regulatory approval process for Mavorixafor and highlights its potential as a promising therapy for patients with WHIM Syndrome.
WHIM syndrome was named after four symptoms: Warts, Hypogammaglobulinemia, Infections, Myelokathexis. WHIM syndrome is a rare and difficult-to-diagnose primary immunodeficiency in which the body’s immune system does not function properly and has trouble fighting infections, especially respiratory, ear, and skin infections.
Mavorixafor is an investigational small-molecule CXCR4 antagonist. It allosterically blocks the overstimulation of the CXCL12/CXCR4 pathway, having the potential to improve immune cell trafficking and immunosurveillance. Mavorixafor was designated orphan drug status by both the U.S. and the EU, and previously granted Fast Track Designation and Breakthrough Therapy Designation by the FDA.